En
The "EFMC-WuXi AppTec Award for Excellence in Chemical Biology" will recognise outstanding research in the field of chemical biology as defined by EFMC in The Chemical Biology-Medicinal Chemistry Continuum: EFMC’s Vision1, ChemBioChem 2021, 22, 2823– 2825.
Applicants should have a track record of significant research achievements in chemical biology during the last 10 years in terms of originality and significance of their research contributions.
The Award shall be open to any scientist whose age does not exceed 50 years* on January 1st of the year during which the Award is to be presented, and whose accomplishment has not yet been honoured by other EFMC awards.
*In accordance with the EFMC core values of equal opportunities and inclusiveness; Maternity leaves, as well as leaves taken for health or private reasons are considered upon making the final selection.
Nominations should consist of:
Self-nominations are also accepted.
The Award will be presented at the EuroChemBio 2027 which will be held in Milan, Italy on October 5-8, 2027.
Deadline for submission: January 31, 2027 | Awardee will be announced around March 2027!
Prof. Stefan Laufer (University of Tübingen, Germany)
For his exceptional, impressive and long-standing contributions to medicinal chemistry and drug discovery. Throughout his career, Professor Laufer has combined scientific excellence, innovation, and leadership to advance the development of novel therapeutic approaches, particularly in the field of kinase inhibitors and inflammation research. Beyond his highly influential scientific achievements, he has played a pivotal role in shaping and strengthening the medicinal chemistry community across Europe. Through his mentorship, collaborations, and commitment to scientific exchange, he has inspired generations of scientists and helped elevate the impact and visibility of our field worldwide.
Prof. Christian Hackenberger (Leibniz-Institute for Molecular Pharmacology, Germany)
For his truly outstanding contributions at the interface of chemistry and biology, particularly through his pioneering work in bioconjugation. Prof. Hackenberger as developed innovative methodologies, such as P5-labeling, that have profoundly advanced the field and have been widely translated in the design of antibody-drug conjugates and in strategies to improve the cellular permeability of biopharmaceuticals. His work, combining deep scientific creativity with a strong translational vision, transformed elegant chemical concepts into approaches with real therapeutic potential, and is widely regarded as a major driver shaping the next generation of therapeutic innovation.
